This announcement is a separate document:
中國抗體-B：自願公告 國家藥監局藥品審評中心受理舒西利單抗(SUCIRASLIMAB, SM03) 用於治療阿爾茨海默病的新藥研究申請
SINOMAB BIO-B: VOLUNTARY ANNOUNCEMENT IND APPLICATION FOR SM03 (SUCIRASLIMAB) FOR THE TREATMENT OF ALZHEIMER''S DISEASE ACCEPTED BY NMPA CDE
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.